At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Zenith® TX2® Low Profile Endovascular Graftdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TRANSFIX - Zenith® TX2® Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury
In Brief
A clinical study evaluating Zenith® TX2® Low Profile Endovascular Graft for Thoracic Aorta and 2 related conditions. Completed, enrolled 50 participants across 21 sites.
Detailed Summary
The TRANSFIX study is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt Thoracic Aortic Injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThoracic Aorta, Thoracic Injuries, Blunt Injuries
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartJan 2013
Primary CompletionJun 2014
Study CompletionJul 2019
TodayJul 2026
First PostedSep 19, 2012
Enrollment StartJan 23, 2013
Primary CompletionJun 1, 2014
Study CompletionJul 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.8 years ago
Interventions
Zenith® TX2® Low Profile Endovascular Graftdevice
Treatment of Blunt thoracic aortic injuries (BTAIs)